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Serotonin has been implicated in the pathogenesis of pul-monary arterial hypertension (PAH)1–3 and has been 
recognized as a potent naturally occurring pulmonary vaso-
constrictor4 and smooth muscle cell mitogen.2 Serotonin pro-
motes pulmonary artery (PA) remodeling and proliferation of 
human PA smooth muscle cells (hPASMCs) via the 5-HT1B 
receptor (5-HT1BR) and the serotonin transporter (SERT).5–8 
Serotonin can also cause constriction of human and rodent 
PAs via the 5-HT1BR.4,9
Reactive oxygen species (ROS), produced primarily by the 
NADPH oxidase (Nox) family of enzymes in the vasculature, 
induce oxidative stress and play a critical role in oxidative 
damage to proteins, lipids, and DNA.10 Altered redox signal-
ing and increased ROS bioavailability have been implicated 
in chronic diseases, including PAH.11,12 Excessive amounts of 
ROS in PAs can oxidize and inactivate signaling molecules, 
such as protein tyrosine phosphatases (PTPs), or can drive 
irreversible protein modification through addition of carbonyl 
groups on protein side chains, a marker for oxidative stress.12,13
Intracellular ROS levels are regulated by the balance 
between ROS-generating enzymes, such as Noxs, and anti-
oxidant enzymes that include superoxide dismutases, catalase, 
and the peroxiredoxin systems,14 which are regulated by a key 
transcription factor Nrf-2 (nuclear factor [erythroid-derived 
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protein tyrosine phosphatases and hyperoxidized peroxiredoxin and decreased Nrf-2 and catalase activity in hPASMCs. ROS 
generation was exaggerated and dependent on cellular Src-related kinase, 5-HT1B receptor, and the serotonin transporter 
in human pulmonary artery smooth muscle cells from PAH subjects. Proliferation and extracellular matrix remodeling 
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signaling and Nox1, confirmed in PASMCs from Nox1−/− mice. In serotonin transporter overexpressing mice, SB216641, a 
5-HT1B receptor antagonist, prevented development of pulmonary hypertension in a ROS-dependent manner.
Conclusions—Serotonin can induce cellular Src-related kinase–regulated Nox1-induced ROS and Nrf-2 dysregulation, 
contributing to increased post-translational oxidative modification of proteins and activation of redox-sensitive signaling 
pathways in hPASMCs, associated with mitogenic responses. 5-HT1B receptors contribute to experimental pulmonary 
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kinase-Nox1-pathways contribute to vascular remodeling in PAH.
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2]-like 2). Nrf-2 activators attenuate experimental pulmonary 
hypertension (PH).15 Increased expression of Nox isoforms 1 
and 4 in PAs has been demonstrated in experimental models of 
PH and in PASMCs from PAH patients.12 Cellular Src-related 
kinase (c-Src) is the predominant nonreceptor tyrosine kinase 
in the vasculature, which is required for regulation of Nox 
activity,16 and this may be dysregulated in PAs of PAH patients 
and experimental PH.17
Serotonin-induced ROS has been implicated in the prolif-
erative response of proximal bovine and murine PASMCs.18,19 
However, it is unclear whether serotonin influences ROS in 
hPASMC and is the focus of our study.
Although studies have shown that serotonin promotes PA 
remodeling mainly through SERT and 5-HT1BR,4,7,20 the role of 
Nox isoforms in serotonin-dependent ROS production, anti-
oxidant regulation, and redox-sensitive processes downstream 
of ROS production has yet to be investigated. It is important 
to investigate this in the distal hPASMCs that contribute to the 
pathophysiology of PAH. For the first time, we investigate the 
role of serotonin in Nox-derived ROS in hPASMCs, specifi-
cally, Nox1-derived ROS in serotonin-induced Nrf-2 dysfunc-
tion, protein carbonylation, and oxidation of antioxidant and 
signaling molecules, peroxiredoxin, and PTPs.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Serotonin Increases ROS Production
Basal ROS production was higher in human pulmonary artery 
smooth muscle cells from PAH subjects (PAH-hPASMCs) 
compared with hPASMCs. In hPASMCs, serotonin increased 
.O2− production at 1, 4, and 24 hours of stimulation, whereas 
in PAH-hPASMCs serotonin increased .O2− generation more 
rapidly at 30 minutes and 1 hour (Figure 1A). In control 
hPASMCs, serotonin-induced .O2− generation was blocked by 
5-HT1BR antagonist, SB224289, but not a SERT antagonist 
(citalopram) or a 5-HT1D/2AR inhibitor (ketanserin). In PAH-
hPASMCs, both the 5-HT1BR and the SERT mediate .O2− gen-
eration as SB224289 and citalopram blocked the effects of 
serotonin (Figure 1B). No effects were observed with sero-
tonin receptor antagonists alone (data not shown).
The Nox1 inhibitor ML171, and the radical scavenger 
tempol, inhibited serotonin-induced ·O2− formation in con-
trol and PAH-hPASMCs (Figure 1C). To control for non-
specific effects of ML171, we examined ROS production in 
mouse PASMCs (mPASMCs) derived from wild-type (WT) 
and Nox1−/− mice. Serotonin-induced ROS production was 
observed in WT mPASMCs but absent in Nox1−/− mPASMCs 
at 30 minutes’ stimulation (Figure 1D).
c-Src may be involved in transactivation and phosphoryla-
tion of subunits required for Nox assembly21 and is a proximal 
regulator of vascular Nox activation.16 Exposure of PAH-
hPASMCs to a Src kinase inhibitor, PP2, inhibited serotonin-
induced ROS in PAH-hPASMCs while having no effect in 
control hPASMCs (Figure 2A).
Hydrogen peroxide (H2O2) is a common substrate for the 
peroxidation reaction of peroxiredoxins.22 Basal intracellu-
lar H2O2 levels, assessed by Amplex red, were increased in 
PAH-hPASMCs versus controls. Serotonin caused H2O2 pro-
duction at 5 and 30 minutes in control hPASMCs, whereas 
H2O2 production in PAH-hPASMCs was more sustained from 
30 minutes to 4 hours (Figure IA in the online-only Data 
Supplement). In control hPASMCs, serotonin reduced cata-
lase activity to similar levels observed in the PAH-hPASMCs, 
whereas in PAH-hPASMCs, serotonin further reduced activity 
of catalase after 5 minutes (Figure IB in the online-only Data 
Supplement). In line with accumulation of H2O2, there was 
a reduction in basal catalase activity in PAH versus control 
hPASMCs (Figure IB in the online-only Data Supplement). 
In addition, catalase activity was reduced by serotonin treat-
ment (30 minutes to 2 hours) in control hPASMCs. In PAH-
hPASMCs, the already lowered basal catalase activity was 
further attenuated by serotonin more rapidly than in the control 
cells, at 5 minutes’ stimulation (Figure IB in the online-only 
Data Supplement). In support, glutathione mRNA levels were 
significantly attenuated in PAH-hPASMCs versus control 
hPASMCs (Figure IC in the online-only Data Supplement).
Regulation of Nox Isoforms by 
Serotonin in hPASMCs
Basal gene expression of Nox1 was increased in PAH-
hPASMCs compared with controls (Figure 2B). Serotonin 
increased Nox1 mRNA expression in control hPASMCs to 
levels observed in PAH-hPASMCs. In PAH-hPASMCs, sero-
tonin also increased mRNA expression of Nox1 (Figure 2B).
Regulation of Nrf-2 and Antioxidant 
Systems by Serotonin
Serotonin increased Nrf-2 activity in control hPASMCs; 
yet, in PAH-hPASMCs, a statistically significant increase 
Nonstandard Abbreviations and Acronyms
5-HT1BR 5-HT1B receptor
c-Src cellular Src-related kinase
H2O2 hydrogen peroxide
hPASMCs human pulmonary artery smooth muscle cells
MMPs matrix metalloproteinases
mPASMCs mouse pulmonary artery smooth muscle cells
PA pulmonary artery
PAH pulmonary arterial hypertension
PAH-hPASMCs human pulmonary artery smooth muscle cells from 
PAH subjects
PDGFR-β platelet-derived growth factor receptor beta
PH pulmonary hypertension
PTP protein tyrosine phosphatase
ROCK rho-kinase
ROS reactive oxygen species
RVH right ventricular hypertrophy
RVSP right ventricular systolic pressure
SERT serotonin transporter
SERT+ serotonin transporter overexpressing mice
WT wild type
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in Nrf-2 activity was not observed with serotonin treatment 
(Figure 2C). Peroxiredoxin is hyperoxidized and inactivated 
through sulfonylation. Basal levels of hyperoxidized perox-
iredoxin in PAH-hPASMCs were elevated compared with 
control hPASMCs. Serotonin increased protein expression of 
hyperoxidized peroxiredoxin in control hPASMCs at 1-hour 
stimulation, and these effects were blocked by 5-HT1BR antag-
onist, SB224289 (Figure 2D).
Serotonin Influences Redox Signaling in hPASMCs
Serotonin increased irreversible PTP oxidation exclusively in 
PAH-hPASMCs, inhibited by 5-HT1BR inhibitor, SB224289, 
and the Nox1 inhibitor, ML171 (Figure 3A; Figure IIA in the 
online-only Data Supplement). Consistent with this, serotonin 
increased irreversible oxidation of PTPs in WT mPASMCs but 
had no effect in Nox1−/− mPASMCs (Figure 3B; Figure IIB in 
the online-only Data Supplement). Carbonylation of proteins 
is a hallmark of oxidative stress. Basal protein carbonylation 
was increased in PAH-hPASMCs versus control hPASMCs, 
with no significant effects of serotonin (Figure 3C). There 
were increased levels of carbonylation in WT, but not Nox1−/−, 
mPASMCs on serotonin treatment (Figure 3D). Basal Rho-
kinase (ROCK) activity was increased in PAH-hPASMCs. 
Serotonin increased activity in PAH-hPASMCs, an effect that 
was inhibited by SB224289 and ML171 (Figure III in the 
online-only Data Supplement).
Serotonin-Induced Proliferation Involves Nox
Serotonin-induced proliferation was increased in PAH-
hPASMCs versus control hPASMCs (Figure 4A). In line with 
ROS production, these effects were attenuated by the 5-HT1BR 
inhibitor and the Nox1 inhibitor in hPASMCs, with additional 
inhibitory effects of SERT inhibitor, citalopram, in PAH-
hPASMCs (Figure 4A). Consistent with this, proliferation was 
reduced in Nox1−/− mouse-derived mPASMCs compared with 
WT mPASMCs when treated with serotonin (Figure 4B).
Serotonin-Induced Alterations in Markers 
of Fibrosis and Extracellular Matrix 
Remodeling Involve Nox1-Derived ROS
Extracellular matrix remodeling is a key process involved in 
the pathobiology of PAH.23,24 Loss of balance between matrix 
Figure 1. Serotonin increases reactive oxygen species (ROS) production through Nox-dependent mechanisms. Time-dependent increase of 
ROS production by serotonin (1 µmol/L) in control human pulmonary artery smooth muscle cells (hPASMCs) and pulmonary arterial hyper-
tension (PAH)-hPASMCs assessed by lucigenin-enhanced chemiluminescence (A). hPASMCs and human pulmonary artery smooth muscle 
cells from PAH subjects (PAH-hPASMCs) were exposed to serotonin for the time of peak ROS production (1 h) previously shown in (A), in the 
presence or absence of inhibitors of Nox1 (ML171, 1 µmol/L) and superoxide dismutase mimetic Tempol (10 µmol/L; B). Serotonin-induced 
ROS production in wild-type (WT) and Nox1−/− mouse pulmonary artery smooth muscle cells (mPASMCs; C). ROS production by serotonin 
(1 µmol/L) in control hPASMCs and PAH-hPASMCs at 1 h stimulation, in the presence or absence of 5-HT1BR antagonist, SB224289, SERT 
inhibitor, citalopram (Cit), or 5-HT2A/1DR antagonist (D). Data are expressed as relative light units (RLU)/µg protein, expressed as percent-
age of vehicle control conditions. Results are mean±SEM of 5 experiments, in triplicate. *P<0.05 vs vehicle control hPASMC or vehicle WT 
mPASMCs; †P<0.05 vs treated control hPASMC; ‡P<0.05 vs vehicle PAH-hPASMCs; §P<0.05, §§P<0.01 vs treated PAH-hPASMCs deter-
mined by ANOVA with Tukey post hoc test. Ket indicates ketanserin; ML, ML171; SB, SB224289; Ser, serotonin; Tem, Tempol; and V, vehicle.
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metalloproteinases (MMPs) and TIMPs (tissue inhibitor of 
matrix metalloproteinases) initiates extracellular matrix and 
vascular remodeling. Basal MMP2 mRNA was elevated in 
PAH-hPASMCs and further increased by serotonin; these 
effects were 5-HT1BR- and Nox1-dependent, through the use 
of pharmacological inhibitors, SB224289 and ML171, respec-
tively (Figure 4C). Basal MMP9 transcript was elevated in PAH-
hPASMCs, and serotonin further stimulated MMP9 in both 
control and PAH-hPASMCs, effects attenuated in the presence 
of 5-HT1BR antagonist, SB224289, and Nox1 inhibitor, ML171 
(Figure 4D). Serotonin had no effect on secretion of platelet-
derived growth factor subunit B (homodimer) from hPASMCs 
(Figure IVA in the online-only Data Supplement). Protein expres-
sion of platelet-derived growth factor receptor beta (PDGFR-β) 
was increased under basal conditions in PAH-hPASMCs ver-
sus control hPASMCs, whereas in control hPASMCs serotonin 
increased expression of PDGFR-β where this increase was 
attenuated in the presence of 5-HT1BR antagonist SB224289 
(Figure IVB in the online-only Data Supplement).
5-HT1BR and Nox1 Staining in 
Human Lung Tissue Sections
In human lung sections from control subjects, 5-HT1BR stain-
ing was absent. In contrast, 5-HT1BR staining was evident in 
Figure 2. Effect of serotonin on Nrf-2 activation and oxidation of peroxiredoxin. Serotonin-induced reactive oxygen species (ROS) 
production in the presence or absence of Src kinase inhibitor, PP2 (10 µmol/L) in control human pulmonary artery smooth muscle cell 
(hPASMC) and pulmonary arterial hypertension (PAH)-hPASMCs. Data are expressed as relative light units (RLU)/µg protein, expressed 
as percentage of vehicle control conditions (A). Transcript levels of Nox1 (B) in response to serotonin. Nuclear translocation of Nrf-2 by 
serotonin at 5 min to 4 h was assessed as an indicator of Nrf-2 activity. Data are expressed as RLU/µg protein expressed as percentage 
of vehicle control conditions (C). Effects of serotonin (1–2 h) in the presence or absence of the 5-HT1BR antagonist, SB224289, on protein 
expression of hyperoxidized peroxiredoxin, hyperoxidized peroxiredoxin (PRDX-SO3H) in hPASMCs (D). Results are mean±SEM of 3 to 
6 experiments. Graph represents mRNA expression relative to GAPDH. *P<0.05, **P<0.01 vs vehicle control hPASMC or wild-type (WT) 
vehicle mouse pulmonary artery smooth muscle cells (mPASMCs); †P<0.05 vs serotonin 1 h control hPASMCs; vehicle human pulmonary 
artery smooth muscle cells from PAH subjects (PAH-hPASMCs; Nox1); ‡P<0.05, ‡‡ P<0.01 vs vehicle PAH-hPASMCs; §§P<0.01 vs sero-
tonin-treated PAH-hPASMCs determined by ANOVA with Tukey post hoc test. ns indicates not significant; SB, SB224289; Ser, serotonin; 
and V, vehicle.
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both the endothelium and the smooth muscle of pulmonary 
arteries in human lung sections from patients with PAH. Nox1 
staining was present in smooth muscle of pulmonary arteries 
of human lung sections derived from both controls and patients 
with PAH (Figure V in the online-only Data Supplement).
5-HT1BR Antagonism In Vivo Attenuates 
Development of PH in the SERT+ Mouse 
and Chronic Hypoxic Mouse
Female mice that overexpress the gene for human SERT 
demonstrate PH.6 Lungs from serotonin transporter over-
expressing (SERT+) mice demonstrated increased oxida-
tive stress.25 The 5-HT1BR antagonist, SB216641, reduced 
the increase in right ventricular systolic pressure (RVSP) 
in SERT+ mice (Figure 5A), and as shown before,6 SERT+ 
mice show no change in right ventricular hypertrophy (RVH; 
Figure 5B). PA remodeling was increased in SERT+ mice, 
and this was reduced by SB216641 (Figure 5C). There was 
no change in mean arterial pressure (Figure VIA in the 
online-only Data Supplement) or heart rate (Figure VIB in 
the online-only Data Supplement) by SB216641 in WT or 
SERT+ mice. In addition, oral administration of SB216641 
(15 mg/kg/d) protected against elevations in RVSP, RVH, and 
the development of pulmonary vascular lesions/remodeling 
in 8- to 10-week-old female C57BL/6J mice exposed to 15 
days chronic hypoxia. Age-matched female mice maintained 
under normoxic conditions were used as controls (Figure 
VII in the online-only Data Supplement). PA remodeling 
was also increased in hypoxic mice compared with their nor-
moxic counterparts, and this remodeling was ameliorated by 
SB216641 (Figure VIII in the online-only Data Supplement). 
No effects were observed in normoxic control mice treated 
with SB216641 (Figures VII and VIII in the online-only Data 
Supplement).
We investigated whether oxidative stress was regulated 
by serotonin (and the 5-HT1BR) in SERT+ mice by immuno-
histochemical analysis of 8-OHG (8-hydroxyguanosine), a 
fluorescent ROS probe, which specifically detects oxidative 
damage to nucleic acids. Female SERT+ mice had increased 
levels of 8-OHG compared with WT mice, and SB21664 
treatment reduced 8-OHG levels (Figure IX in the online-only 
Data Supplement). 8-OHG staining was observed in both the 
Figure 3. Effects of serotonin on oxidation of protein tyrosine phosphatases (PTPs) and global protein carbonylation. Irreversible oxi-
dation of PTPs using the oxPTP antibody, in response to serotonin in human pulmonary artery smooth muscle cells (hPASMCs) in the 
presence or absence of SB224289 or Nox1 inhibitor, ML171 (A). PTP oxidation in wild-type (WT) and Nox1−/− mouse pulmonary artery 
smooth muscle cells (mPASMCs) treated with serotonin (B). Total protein carbonylation in response to serotonin in hPASMCs (2 h; 
C) and in Nox1−/− mPASMCs (1 h; D). Results are representative of 3 to 5 experiments where protein expression is relative to β-actin. 
*P<0.05, **P<0.01, vs vehicle control hPASMCs or WT vehicle mPASMCs; †P<0.05 vs treated WT mPASMCs; ‡‡P<0.01 vs vehicle pul-
monary arterial hypertension (PAH)-hPASMCs; §P<0.05, §§P<0.01 vs serotonin-treated human pulmonary artery smooth muscle cells 
from PAH subjects (PAH-hPASMCs) determined by ANOVA with Tukey post hoc test. ML indicates ML171; SB, SB224289; Ser, sero-
tonin; and V, vehicle.
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cytoplasm and the nucleus, indicating increased RNA and 
DNA oxidation.
Discussion
Our novel findings demonstrate that in hPASMCs serotonin 
stimulates ROS through Nox, downregulates protective anti-
oxidant mechanisms, stimulates redox signaling and irre-
versible protein oxidation and carbonylation, and promotes 
molecular and cellular processes associated with extracel-
lular matrix remodeling and cell growth. These serotonin 
effects are amplified in hPASMCs from patients with PAH 
and involve c-Src–regulated Nox1 and 5-HT1BR and Nrf-2 
dysfunction (summarized in Figure X in the online-only Data 
Supplement). Using SERT+ mice, we confirm, in vivo, our 
cell-based findings.
The 5-HT1BR receptor is highly expressed in human 
PAs, with increased expression in PAH patients,4 and medi-
ates serotonin-induced vasoconstriction and PA remodeling. 
The 5-HT2AR mediates these effects systemically and so the 
5-HT1BR effects are pulmonary specific, making it a favor-
able target for PAH. Serotonin-dependent ROS production in 
hPASMCs was dependent on 5-HT1BR in control hPASMCs, 
whereas in PAH-hPASMCs this was mediated by both the 
SERT and the 5-HT1BR. Consistently, there is an increase in 
SERT expression in PAs and hPASMCs from PAH patients.26 
Female mice overexpressing SERT have a PH phenotype.6 
There is co-operation between SERT and 5-HT1BR in human 
and experimental PAH,5,20 and dual blockade of the 5-HT1BR 
and SERT is a plausible therapeutic approach.
Growing evidence implicates a role for Noxs, particu-
larly Nox1 and Nox4, in the pathogenesis of experimental 
and human PAH.12,27 In addition to the constitutive expression 
of Nox1 in a variety of tissues, Nox1 expression is increased 
after inflammation, growth factor stimulation, and hypoxia.28 
Nox1 also plays a critical role in physiological turnover of 
PASMCs by regulation of intracellular potassium.29
We observed that serotonin induces ROS production 
through Nox1 activation in hPASMCs. Although peak ROS 
levels induced by serotonin are similar between control 
and PAH-hPASMCs, we suggest that PAH-hPASMCs are 
already primed to ROS, as basal levels are increased in PAH-
hPASMCs versus control hPASMCs. We note that although 
Figure 4. Role of 5-HT1BR and Nox1 in serotonin-mediated cell proliferation and extracellular matrix remodeling. To test whether sero-
tonin regulates proliferation in a Nox/reactive oxygen species (ROS)-dependent manner, BrdU (5-Bromo-2′-deoxyuridine) incorporation 
was assessed in human pulmonary artery smooth muscle cells (hPASMCs; A) and wild-type (WT) and Nox1−/− mouse pulmonary artery 
smooth muscle cells (mPASMCs) in response to serotonin (B). Transcript expression of MMP2 (C) and MMP9 (D) after treatment with 
serotonin with or without SB224289 or ML171. Results are representative of 5 experiments per group where mRNA expression is normal-
ized to GAPDH. *P<0.05, **P<0.01, ***P<0.001 vs vehicle control hPASMCs or WT vehicle mPASMCs; †P<0.05, ††P<0.01 vs serotonin-
treated control hPASMCs; ‡P<0.05 vs vehicle pulmonary arterial hypertension (PAH)-hPASMCs or serotonin-treated mPASMCs; §P<0.05, 
§§P<0.01 vs serotonin-treated PAH-hPASMCs determined by ANOVA with Tukey post hoc test. Cit indicates citalopram; ML, ML171; 
MMP, matrix metalloproteinase; SB, SB224289; Ser, serotonin; and V, vehicle.
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ROS levels were sustained in control hPASMCs, they were 
quickly recovered in PAH-hPASMCs. Although glutathione 
transcript level is reduced in PAH versus control hPASMCs, 
there is no further impairment after serotonin stimulation. 
Similarly, although catalase activity is downregulated by sero-
tonin in control hPASMCs up to 2 hours, in PAH-hPASMCs, 
catalase activity recovers more rapidly than in control 
hPASMCs. Moreover, we found that this effect is mediated 
via c-Src because PP2, which inhibits Src family kinases, 
attenuated serotonin-induced Nox1 activation. c-Src plays an 
important role in activation of MAPKs associated with cell 
growth, apoptosis, and collagen deposition.30 Previous stud-
ies demonstrated that c-Src is both a redox-sensitive down-
stream target of Nox and an upstream signaling molecule for 
Nox activation31 and can increase protein abundance subunits 
and adaptor proteins required for regulation of Nox activity.16 
Importantly, PP2 reduced serotonin-stimulated ROS forma-
tion exclusively in PAH-hPASMCs, suggesting a role for 
c-Src in serotonin-mediated Nox activation in PAH.
High concentrations of ROS trigger the oxidation of PTPs, 
resulting in their loss of function as a phosphate acceptor.32 
In association with excessive ROS production by serotonin, 
we found an increase in irreversibly oxidized PTPs. Our find-
ings suggest that PTP inhibition may play a role in PAH and 
that serotonin-induced Nox1-derived ROS may be important 
in this process.
Other molecular processes that are redox-sensitive relate 
to total protein carbonyl content, an important index of whole 
cell protein oxidation.33 Accumulation of protein carbonyls 
has been observed in several human pathologies, including 
diseases of the lung.34 We found increased protein carbon-
ylation in basal conditions, in PAH-hPASMCs compared 
with control cells, along with increased carbonyl content in 
response to serotonin in WT mPASMCs, an effect that was 
absent in mPASMCs from Nox1−/− mice. This suggests a role 
for Nox1-derived ROS in the regulation of protein carbonyl-
ation in hPASMCs. It has been reported that an alternative 
strategy to antioxidant intervention is to detoxify oxidative-
derived carbonyl reaction products.35 Thus, strategies to regu-
late carbonyl content may have clinical value.
Peroxiredoxin is an antioxidant enzyme important in the 
degradation of H2O2, which can modulate various receptor 
signaling pathways and protects cells from oxidation-induced 
death. The active site cysteine (Cys) of peroxiredoxin is oxi-
dized to the sulfenic acid intermediate (Cys-SOH) when a 
peroxide is reduced. Yet, because Cys-SOH is unstable, it 
forms a disulfide with Cys-SH. However, under oxidative 
stress conditions, the sulfenic intermediate (Cys-SOH) can 
Figure 5. Hemodynamic assessment of pulmonary hypertension in female wild-type (WT) and serotonin transporter overexpressing 
(SERT+) mice treated with SB216641. Right ventricular systolic pressure (RVSP; A), right ventricular (RV) hypertrophy (B). Effects of 
SB216641 on percentage of pulmonary vascular remodeling in distal pulmonary arteries in female WT and SERT+ mice with representa-
tive images (right) of pulmonary arteries (Elastin Van Gieson stain; scale bars=50 µm; C). Results are mean±SEM, n=8 to 10 per group. 
***P<0.001 vs WT vehicle, †††P<0.001 vs SERT+ vehicle, determined by 2-way ANOVA with Tukey post hoc test. Data are mean±SEM. 
n=8 to 10 per group. **P<0.01 vs WT vehicle; †P<0.05 vs SERT+ vehicle, determined by 2-way ANOVA with Tukey post hoc test.
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be easily overoxidized to cysteine sulfinic or sulfonic (Cys-
SO2H/-SO3H) acids, referred to as hyperoxidation. H2O2 is a 
common substrate for the peroxidation reaction of peroxire-
doxins and also a well-known cause for their hyperoxidation.22 
In our study, serotonin caused excessive production of H2O2 in 
PAH-hPASMCs, as well as decreased activity of H2O2 reduc-
ing enzymes, catalase, and glutathione, in PAH-hPASMCs 
versus control hPASMCs. These effects were further reduced 
in serotonin-treated PAH-hPASMCs, indicative of increased 
production and accumulation of H2O2 in PAH, potentiated by 
serotonin. In control hPASMCs, serotonin stimulated ROS 
production and increased Nrf-2 activity, perhaps as a com-
pensatory mechanism to maintain redox balance. However, 
in PAH-hPASMCs, serotonin increased ROS production, yet 
did not induce activity of Nrf-2 as an antioxidant defense 
mechanism, suggesting overall ROS accumulation and oxida-
tive damage. Of clinical significance, Nrf-2 activators are in 
human trials for PAH and can attenuate experimental PH.15
To better understand the functional significance of sero-
tonin-induced oxidative stress, we studied effects on molec-
ular regulators of vascular contraction and proliferation, 
hallmarks of vascular remodeling in PAH. In human PAH, 
ROCK inhibitors cause modest reductions in pulmonary vas-
cular resistance.36 As such, ROCK has been implicated in both 
PA contraction and remodeling.37 Serotonin-induced PASMC 
proliferation, contraction, and migration involve ERK1/2 
MAPK and ROCK. Serotonin-mediated signaling of ROCK 
occurs through 5-HT1BR activation in a lung fibroblast cell 
line.8 Here, we show in hPASMCs that serotonin-mediated 
activation of ROCK is mediated via the 5-HT1BR and Nox1-
derived ROS. Serotonin stimulated cell proliferation, which 
was exaggerated in PAH-hPASMCs and dependent on the 
5-HT1BR and Nox1 because these effects were absent in 
the presence of inhibitors of this receptor and oxidase, and 
in Nox1−/− mice. Apoptosis is another key factor in vascular 
remodeling characteristic of PAH, as such, it has been previ-
ously shown that serotonin inhibits PASMC apoptosis through 
5-HT1BR or SERT.38 It would be interesting to understand the 
role of serotonin and the 5-HT1BR in other vascular cell com-
ponents, such as human PA endothelial cells, primary cultures 
of such cells are not readily available from control subjects 
and patients with PAH, and therefore are difficult to study in 
relation to the human disease.
Structural remodeling of pulmonary arteries through 
smooth muscle cell migration, proliferation, and oversecre-
tion of extracellular matrix are the most notable pathologi-
cal changes in PAH.39 The MMPs, particularly gelatinases 
MMP2 and MMP9, are involved in extracellular matrix turn-
over and hence, in smooth muscle cell migration and prolif-
eration. Of note, promoters of functionally related MMPs, 
such as MMP2/MMP9, are clearly distinct, pointing to dif-
ferent mechanisms of activation.40 As evidenced here and as 
shown previously, concomitant increments in both MMPs are 
not always observed. For example, in a rat model of pancre-
atitis-induced lung injury, MMP9 increased in lung tissue, 
whereas MMP2 remained unchanged.41 However, the promo-
tor for MMP2 does not harbor a TATA box, and expectedly, 
transcription from these promoters starts at multiple sites. 
Such that, expression of MMP2 is mainly determined by the 
ubiquitous Sp1 family of transcription factors, where expres-
sion of MMP2 in the main part is constitutive, with only mod-
est sensitivity to induction by growth factors or cytokines.42 
This is in line with our data showing that MMP2 transcript 
is induced by serotonin solely in PAH-hPASMCs, whereas 
MMP9 mRNA expression is sensitive to serotonin stimula-
tion in both control and PAH-hPASMCs. Vascular remodel-
ing in both experimental and human PAH has been shown to 
involve increased expression of profibrotic proteins. In the 
lung of PAH patients, accelerated turnover of the extracellu-
lar matrix because of increased MMP activity occurs.23 Loss 
of balance between MMPs and TIMPs initiates extracellular 
matrix and vascular remodeling and is involved in a variety 
of pathologies.43 Serotonin increased expression of the pro-
fibrotic signaling proteins MMP2 and MMP9 in hPASMCs. 
These effects were absent in hPASMCs pretreated with inhibi-
tors of the 5-HT1BR or Nox1, suggesting an important role for 
Nox1 in the profibrotic effects of serotonin.
The rationale for platelet-derived growth factor involve-
ment in the pathogenesis of PAH is strong, with increased 
expression of ligand and phosphorylated receptor in patient 
lung tissue.44 However, we did not observe any change in the 
platelet-derived growth factor subunit B (homodimer) levels 
in the spent culture medium from serotonin-stimulated control 
and PAH-hPASMCs. Because both serotonin and PDGFR-β 
have been associated with clinical and experimental PH, 
and patients with PA hypertension have enhanced activation 
of PDGFR-β in their lungs,44 we investigated whether there 
is a relationship between these molecules in  hPASMCs. 
Expression of PDGFR-β was increased under basal conditions 
in PAH-hPASMCs versus control hPASMCs, whereas in con-
trol hPASMCs, serotonin increased expression of PDGFR-β, 
where this increase was absent in the presence of 5-HT1BR 
antagonist SB224289. A previous study in bovine-derived 
PASMCs observed serotonin-stimulated production of ROS 
serving as an intermediate in the transactivation of PDGFR-β 
by serotonin, where oxidation of PTPs was suggested as 
the mechanism involving SERT rather than the 5-HT recep-
tors.45 In line, we observed that in female human PASMCs, 
PDGFR-β expression is increased in PAH-hPASMCs ver-
sus control hPASMCs. In control hPASMCs, expression of 
PDGFR-β was elevated by serotonin in a 5-HT1BR–dependent 
manner. This is consistent with recognized cross talk between 
platelet-derived growth factor and serotonin signaling in pul-
monary arteries.46
To test the pathophysiological significance of our find-
ings, we performed in vivo studies assessing the effects of the 
5-HT1BR antagonist, SB216641, in 2 mouse models of PH, 
the chronic hypoxic mouse, and in a serotonin-dependent 
mouse model of PH, the SERT+ mouse. Female C57BL6/J 
mice exposed to hypoxic conditions developed elevated 
RVSP, RVH, and evidence of pulmonary vascular remodeling 
parameters, which were prevented in those mice treated with 
the 5-HT1BR antagonist, SB216641. Similarly, female SERT+ 
mice developed increased RVSP and PA remodeling at 20 
weeks of age; protective effects of SB216641 treatment was 
observed. RVH remained unaffected, in line with previous 
work where our group and others have shown a dissociation 
between RVSP and RVH in the SERT+ mouse.6 We previously 
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demonstrated increased ROS expression in the SERT+ mouse 
lung25; lung ROS was reduced by the 5-HT1BR antagonist, 
suggesting that the 5-HT1BR/ROS axis is important both in 
vitro in cultured PASMCs and in vivo in the mouse lung. In 
addition, in support of the role of 5-HT1BR in human PAH, 
we observed marked 5-HT1BR staining in the endothelium and 
smooth muscle cell layers of the vasculature in human lung 
sections from PAH subjects, staining that was absent in lung 
sections from control subjects.
In conclusion, we show for the first time in hPASMCs 
from PAH patients that serotonin increases Nox1-dependent 
ROS generation and decreases Nrf-2-antioxidant systems 
through c-Src–dependent processes that contribute to oxida-
tion of proteins, DNA damage, and redox-sensitive prolifera-
tion and fibrosis of hPASMCs, processes involved in PAH. 
In line, we observed ROS-dependent protective effects of 
5-HT1BR antagonism in the SERT+ mouse model of PH. We 
identify the 5-HT1BR and both 5-HT1BR and SERT in PAH-
derived PASMCs, as being particularly important in Nox1-
derived ROS production and in serotonin-mediated vascular 
effects in PAH. Our study provides new molecular insights 
through c-Src/Nox1/ROS and Nrf-2 antioxidant mechanisms, 
whereby serotonin influences hPASMC function, which when 
upregulated may contribute to vascular injury in PAH (sum-
marized in Figure X in the online-only Data Supplement).
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Highlights
• Serotonin-induced proliferation of vascular cells, via the serotonin transporter and the 5-HT1B receptor, has been associated with the develop-
ment of pulmonary arterial hypertension.
• Serotonin stimulates production of reactive oxygen species but mechanisms underlying this, and the significance of serotonin-induced reactive 
oxygen species in the development of pulmonary arterial hypertension, remain unclear. Here, we show that redox-sensitive effects of serotonin 
are associated with Nrf-2 dysregulation, contributing to oxidative stress, protein oxidation, proliferation, and extracellular matrix remodeling in 
pulmonary artery smooth muscle cells from pulmonary arterial hypertension patients.
• We demonstrate in vivo that this may contribute to the pathobiology of pulmonary hypertension.
• Therefore, inhibition of the serotonin-mediated redox system or activation of Nrf-2 could be novel therapeutic strategies in pulmonary arterial 
hypertension.
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*Joint senior authors 
 
Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom. 
 
  
1 
 
Cell Culture 
In vitro studies were performed using primary hPASMC from distal arteries from PAH 
patients (PAH-hPASMCs). Cells were explanted as described1, and were provided by N.W. 
Morrell, University of Cambridge, UK. PASMCs from non-PAH subjects (control 
hPASMCs) were also studied (patient details in Supp. Table I) where PAH was not suspected 
on clinical or radiological grounds in these subjects and cells were derived from 
macroscopically normal tissue. Experimental procedures using hPASMCs were approved by 
Cambridgeshire 1 Research Ethics Committee (reference: 08/H0304/56). Additional in vitro 
studies were performed in primary cultured mouse PASMCs (mPASMCs) from the intralobar 
pulmonary arteries of female Nox1-/- mice and WT littermates (C57BL/6J background), used 
between passage 2 and 4, as described previously2. 
 
Cell Protocols 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, UK) 
supplemented with antibiotic antimycotic solution (containing 0.25µg/ml amphotericin B; 
100U/ml penicillin; 100µg/ml streptomycin; Sigma-Aldrich, UK) and 10% (v/v) fetal bovine 
serum (Sera Laboratories International, West Sussex, UK). Cells were grown to 70% 
confluence before serum deprivation for 24 hours in 0.5% fetal bovine serum in phenol-red 
free DMEM prior to experiments to render them quiescent. Cells were stimulated with 
serotonin (1µmol/L; 5 minutes-24 hours). In some protocols, cells were pre-treated (30 
minutes) with pharmacological inhibitors Acetylphenothiazine (ML171; Nox1 inhibitor, 
1µmol/L); 1'-Methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-
yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidinehydrochloride 
(SB224289; 5-HT1BR antagonist, 0.1µmol/L); 3-[2-[4-(4-Fluorobenzoyl)-1-
piperidinyl]ethyl]-2,4[1H,3H]-quinazolinedione tartrate (ketanserin; 5-HT2A/1DR antagonist, 
0.1µmol/L); 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-
isobenzofurancarbonitrile hydrobromide (citalopram; SERT inhibitor, 0.1µmol/L); 4-Amino-
3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo[3,4-d] pyrimidine (PP2; c-Src inhibitor, 
0.1µmol/L); 4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (tempol; SOD mimetic, 
10µmol/L). Doses were based on preliminary experiments and published data. 
Reagents and Antibodies 
The following antibodies were used: anti-PRDX-SO2/SO3H (Abcam, ab16830); anti-PCNA 
(Santa Cruz, sc-56); anti-Nox1 (Abcam, ab55831); anti-Ox-PTP (R&D systems, MAB2844) 
and anti-β-actin (Abcam, ab8229). Serotonin (Cat.#3547), PP2, a Src kinase inhibitor 
(Cat.#P0042) and SB224289, (5-HT1B R antagonist; Cat.#S201); ML171 (Nox1 inhibitor; 
Cat.#4653); Tempol (SOD mimetic; Cat.#3082); Ketanserin (5-HT2A/1DR antagonist; 
Cat#0908) and Citalopram (SERT inhibitor; Cat#1427) were purchased from Tocris, UK. 
Doses were based on preliminary experiments and published data. 
 
Lucigenin-Enhanced Chemiluminescence  
Lucigenin-enhanced chemiluminescence was used to determine ROS generation as described 
previously3. ROS production was determined in control hPASMC, PAH-hPASMCs and 
mPASMCs stimulated with serotonin for 5 minutes to 48 hours. Inhibitor studies (30 
minutes’ pre-incubation) were carried out at the peak time points for ROS production (1 
hour). After stimulation, cells were washed with ice-cold PBS and harvested in lysis buffer 
(20mmol/L KH2PO4, 1 mmol/L EGTA, 1μg/mL aprotinin, 1μg/mL leupeptin, 1μg/mL 
pepstatin, and 1mmol/L PMSF). 50µl of sample was added to a suspension containing 175μl 
of assay buffer (50mmol/L KH2PO4, 1mmol/L EGTA,150mmol/L sucrose) and lucigenin 
(5μmol/L). NADPH (100µmol/L) was added to the suspension containing lucigenin 
(5µmol/L). Luminescence was measured with a luminometer (AutoLumat LB 953, Berthold) 
2 
 
before and after stimulation with NADPH. A buffer blank was subtracted from each reading. 
Superoxide anion production was inhibited by tempol and was expressed as relative 
luminescence units (RLU)/µg protein, relative to vehicle conditions. For analysis, basal 
relative light units (RLU) values were subtracted from NADPH-stimulated values. RLU were 
corrected to sample protein concentration (µg/ml), as assessed by DC assay (Bio-Rad). 
Results in RLU/ug protein were then normalised to their respective vehicle control hPASMCs 
data. Data is expressed as relative percentage (%) of vehicle control hPASMCs. 
 
Amplex Red Assays  
H2O2 production and catalase activity was assessed with Amplex Red Hydrogen 
Peroxide/Peroxidase Assay, or Amplex Red Catalase Assay, (Thermo Fisher, UK) according 
to instructions, as described previously4.  
 
Real-Time PCR  
Quantitative real-time PCR was used to analyse mRNA expression using SYBR Green I as 
previously described4. Primers used were designed using the Primer 3 software online (Supp. 
Table II).  
 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) Activity Assay  
Nrf-2 activity was determined with the TransAM Nrf-2 assay (Active Motif, USA) following 
manufacturer’s instructions. Briefly, to assess Nrf-2 nuclear accumulation, samples were 
prepared according to the manufacturer’s protocol using a nuclear extract kit (Active Motif, 
USA). Nuclear preparations (10μg) were used for the TransAM Nrf2 ELISA kit (Active 
Motif, USA) to measure DNA binding of activated Nrf2 nuclear protein, as determined by 
absorbance measurements at 450nm, as described4.  
 
Measurement of Rho Kinase Activity 
Rho kinase (ROCK) activity was assessed using the ROCK Activity Assay (Cell Biolabs Inc) 
following manufacturer’s instructions5. 
 
Measurement of PDGF-BB levels 
PDGF-BB levels in spent medium from control and PAH-hPASMCs, was assessed using the 
PDGF-BB ELISA (R&D Systems, cat# DBB00) according to manufacturer’s instructions. 
 
Immunoblotting  
Proteins were extracted from hPASMCs and protein expression of PDGFR-β (Abcam; cat# 
ab32570) and hyper-oxidized peroxiredoxin (PRDX-SO3H) was examined by 
immunoblotting as described previously6. All antibodies were used at 1:1000 dilution unless 
otherwise stated. Washed membranes were incubated with horseradish peroxidase -
conjugated secondary antibodies and probed for immunoreactive proteins by 
chemiluminescence (WestPico, Pierce).  
 
Protein tyrosine phosphatase oxidation  
Irreversible oxidation of PTPs was assessed using anti-Ox-PTP antibody that recognizes the 
sulfonic acid form of PTP cysteine residues. Briefly, irreversible oxidation of protein tyrosine 
phosphatases (PTPs) was assessed by immunoblotting using an antibody (anti-Ox-PTP; 
1:2000 dilution, R&D Systems) that specifically recognizes the sulfonic acid form of PTP 
cysteine residues. Following treatment, the sample is alkylated using N-ethylmaleimide 
(NEM; 1mmol/L) to protect reduced cysteines. Subsequently, the samples are treated with 
dithiothreitol (DTT; 1mmol/L) and pervanadate (100µmol/L) to convert reduced cysteines to 
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the sulfonic acid form. Finally, the sulfonic acid form is detected using the Ox-PTP antibody 
by immunoblotting as previously described7. 
 
OxyBlot 
Protein carbonylation was assessed by OxyBlot Protein Oxidation Detection Kit (Millipore) 
following manufacturer’s instructions8. 
 
5-Bromo-2'-deoxyuridine (BrdU) Incorporation Assay  
Proliferation was measured using the BrdU Incorporation assay (Millipore) following 
manufacturer’s instructions as described6. Briefly, cells were seeded onto a 96-well plate and 
starved overnight before stimulation. Cells were incubated with BrdU for 24 hours. 
Absorbance was obtained at dual wavelength (450nm and 595nm) with a spectrophotometer 
(Spectra Max; Molecular Devices, Sunnyvale, CA, USA). The results were normalized as 
percent of control vehicle conditions 
 
Ethical Considerations: SERT+ mice and C57BL/6J mice 
The investigation conforms with the UK Animal Procedures Act (1986) and ARRIVE 
Guidelines. All mice used were 20-week-old females. Mice were housed in controlled 
environmental conditions with a 12-hour light/dark cycle with free access to food and water. 
 
SERT+ Mice 
SERT+ mice (background: C57BL/6JxCBA) have been previously described9. 20-week old 
female SERT+ mice underwent 14-days treatment with 5-HT1BR antagonist (SB216641; 
15mg/kg/day, oral gavage) or vehicle (dH2O). Age-matched littermates were studied as 
controls. 
 
Chronic Hypoxia Model of Pulmonary Hypertension 
Female C57BL/6J mice (aged 8-10 weeks) were exposed to hypoxic conditions for 15 days 
using a hypobaric chamber. Age-matched normoxic female mice were assessed as controls. 
From days 1 to 15, mice underwent treatment with either 5-HT1BR antagonist (SB216641; 
15mg/kg/day, oral gavage) or vehicle (dH2O). 
 
In vivo Haemodynamic Measurements 
Pressure measurements were conducted and analysed as described previously10. Inhalation 
anaesthesia was used throughout the procedure (1–3% isoflurane/O2). Depth of anaesthesia 
was assessed by loss of pain and corneal reflexes. Briefly, right ventricular systolic pressure 
(RVSP) was measured via a 25-gauge needle advanced into the right ventricle (RV) using a 
trans-diaphragmatic approach. Mean systemic arterial pressure (mSAP) was obtained via a 
micro-cannula inserted into the carotid artery. Mice were euthanized by cervical dislocation 
and heart and lungs removed for subsequent analysis as described below. Eight to 10 mice 
per group were studied. 
 
Measurement of Right Ventricular Hypertrophy 
Right ventricular hypertrophy (RVH) was assessed as weight of the RV free wall/ weight of 
the left ventricle with the septum. 
 
Human Lung Immunohistochemistry  
Formalin-fixed, paraffin embedded tissue sections from human control lung and human PAH 
lung, were stained using anti-5-HT1BR antibody (Abcam ab13896 1:400), and anti-Nox1 
antibody (Sigma, SAB4200097; 1:200). An anti-rabbit IgG secondary antibody was used for 
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each primary antibody (5µg/ml; Vector Laboratories IMMpress kit) and protein immuno-
localisation was visualized with the alkaline phosphatase substrate kit (Vector labs UK; sk-
5100).  
 
Lung Immunohistochemistry to assess PA remodeling  
At harvest, the lung was perfusion-fixed via the trachea, processed into paraffin where 
sections (3µm) were cut and stained for elastin and collagen using Millers Elastin and Picro-
Sirius red for identification of vascular thickening. Remodeling of pulmonary arteries distal 
to the airways, was defined by the presence of a double elastic lamina and/or by an increase 
in the vessel wall diameter in more than 50% of the arterial wall. The total number of 
remodelled vessels was expressed over the total number of vessels present in a lung section 
as assessed by a blinded investigator, where at least 100 pulmonary arteries of <80μm 
external diameter per lung were scored. Lung sections from six mice from each group were 
studied. Analysis was carried out in a blinded fashion as described previously11.  
 
Reactive Oxygen Species Determination in Lung Sections by Immunofluorescence  
Immunohistochemistry of the ROS marker 8-hydroxyguanosine (8-OHG) was determined in 
the lungs of wild-type (WT) and SERT+ mice treated with 5-HT1BR antagonist, SB216641, 
or vehicle, as previously described12. Briefly, sections were deparaffinised in a xylene-
ethanol-water gradient. Antigen retrieval was performed by boiling slides in EDTA (pH 8.0) 
for 15 minutes before a 1-hour incubation in a humidified chamber at room temperature with 
10% donkey serum/1% bovine serum albumin in 1× TBS-T to block non-specific binding. 
Sections were incubated with anti- 8-OHG overnight at 4°C (5 μg/mL, ab10802, Abcam). For 
identification of 8-OHG-positive cells, sections were incubated with Alexa-fluor-488-
conjugated donkey anti-goat secondary antibody (A-11055, Molecular Probes, Life 
Technologies, UK) for 45 minutes at room temperature in the dark. Lipofuscin-mediated 
auto-fluorescence was removed with 0.1% Sudan Black B (Sigma-Aldrich) in methanol w/v 
for 10 minutes. Slides were mounted with Pro-Long Gold anti-fade mounting media 
containing DAPI (4′,6-diamidino-2-phenylindole; P-36931, Molecular Probes, Life 
Technologies). Fluorescence imaging was measured in an Axiovert 200M microscope with a 
laser-scanning module LSM 510 (Carl Zeiss, Germany). DAPI was excited at 405nm and 
Alexa-Fluor 488 at 488nm. Images were captured with the LSM 510 Zen evaluation software 
(Zeiss, UK).  
 
Statistical Analysis  
Mean values ± SEM were calculated and statistical comparisons made using Graph Pad 
Prism 7.02 software, with 1-way or 2-way ANOVA followed by Tukey’s post hoc test or 
two-tailed Student’s-t-test where appropriate. P<0.05 was considered statistically significant 
(*).  
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Table I. PAH Patient and non-PAH patient information. 
Patient Group Sex Age (years) Disease Status 
Non-PAH Female 
 
57 COPD 
58 Mild emphysema  
59 Squamous cell carcinoma 
64 Lung carcinoma 
70 Lobectomy 
PAH Female 
 
30 HPAH (R899X) 
33 IPAH 
39 IPAH 
41 HPAH (N903S) 
53 IPAH 
 
Pulmonary artery smooth muscle cell subject origin and characteristics. Known 
characteristics of subjects from whom cells were derived. COPD, chronic obstructive 
pulmonary disease; HPAH, heritable pulmonary arterial hypertension (gene mutation in 
parenthesis); IPAH, idiopathic pulmonary arterial hypertension. 
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Table II. Human primers for real time PCR analysis. 
Human 
Gene 
Forward Primer Reverse Primer 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG 
MMP2 TCTCCTGACATTGACCTTGGC CAAGGTGCTGGCTGAGTAGATC 
MMP9 TTGACAGCGACAAGAAGTGG GCCATTCACGTCGTCCTTAT 
Nox1 TCACCAATTCCCAGGATTGA TGTGGTCTGCACACTGGAAT 
GPx AGTCGGTGTATGCCTTCTCG TTGAGACAGCAGGGCTCGAT 
 
Human primers targeted to the above genes were designed using Primer 3 software, and were 
used to assess gene expression in control hPASMCs and PAH-hPASMCs.  
 
Supplemental Figure I
Supplemental Figure I: Effect of serotonin on H2O2 and antioxidants, catalase and glutathione. H2O2
production (A) and catalase activity (B) in hPASMCs was measured by Amplex Red assay in cells exposed
to serotonin for 5 minutes to 4 hours. Data are expressed as RLU/µg protein corrected to standard curve and
expressed as percentage of vehicle conditions. Glutathione mRNA expression (C) in hPASMCs. mRNA
expression is relative to GAPDH. Results are mean ± SEM of 5-6 experiments, in triplicate. *p<0.05,
**p<0.01 vs. vehicle control hPASMC; ‡p<0.05 vs. vehicle PAH-hPASMCs determined by ANOVA with
Tukey’s post-hoc test. V= vehicle; Ser= serotonin; SB= SB224289.
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Supplemental Figure II: Serotonin promotes oxidation of PTPs. Irreversible oxidation of PTPs using the
oxPTP antibody, in response to serotonin in the presence or absence of 5-HT1BR antagonist SB224289 or
Nox1 inhibitor, ML171 in hPASMCs (A) and in WT and Nox1-/- mPASMCs (B). Values are mean ± SEM of
4 experiments. Protein expression is relative to β-actin. Representative blots corresponding to Figure 3A and
3B. V= vehicle; SB= SB224289; ML= ML171; WT= wild-type.
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Supplemental Figure III
Supplemental Figure III: Role of 5-HT1BR and Nox1 in serotonin-mediated vascular contraction. Rho
Kinase activity assay was used to assess serotonin-induced Rho kinase activity in hPASMCs. Results are
expressed as mean±SEM of 5 experiments relative to protein concentration. *p<0.05 vs vehicle control
hPASMCs; ‡p<0.05 vs vehicle PAH-hPASMCs; §p<0.05 vs treated PAH-hPASMCs determined by ANOVA
with Tukey’s post-hoc test. V= vehicle; Ser= serotonin; SB= SB224289; ML= ML171.
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Supplemental Figure IV 
Supplemental Figure IV: Effect of serotonin on secretion of PDGF-BB and PDGFR-β expression. 
Secretion of PDGF-BB into hPASMC culture supernatant assessed by ELISA (A). Expression of PDGFRB 
in response to serotonin in hPASMCs (B). Results are mean ±SEM, n=6 per group. ns: not significant. 
*p<0.05; **p<0.01 vs vehicle control hPASMCs; †p<0.05 vs serotonin-treated control hPASMCs. V= 
vehicle; Ser= serotonin; SB= SB224289.
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Supplemental Figure V
Supplemental Figure V: 5-HT1B receptor and Nox1 staining in human control and PAH lung sections. 
5-HT1B receptor and Nox1 staining in human pulmonary arteries in lung sections from controls and PAH 
patients, counterstained with haematoxylin. Scale bars = 100 microns. n=2-5 per group. 
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Supplemental Figure VI
Supplemental Figure VI: Haemodynamic assessment of pulmonary hypertension in female WT and 
SERT+ mice treated with SB216641. Mean systemic arterial pressure (mSAP) (A) and heart rate (HR) (B). 
Results are mean ±SEM, n=8-10 per group. ns: not significant. WT = wild-type, BPM = beats per minute. 
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Supplemental Figure VII
Supplemental Figure VII: Haemodynamic assessment of pulmonary hypertension in female normoxic
and hypoxic mice treated with SB216641. Right ventricular systolic pressure (RVSP) (A), right ventricular 
hypertrophy (B), mean systemic arterial pressure (mSAP) (C) and heart rate (HR) (D). Results are mean 
±SEM, n=8-10 per group. *p<0.05; ***p<0.001 versus normoxic vehicle treated mice; †p<0.05 versus 
hypoxic vehicle treated mice. BPM = beats per minute. 
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Supplemental Figure VIII
Supplemental Figure VIII: Pulmonary vascular remodelling in female normoxic and hypoxic mice 
treated with SB216641. Effects of SB216641 on percentage of pulmonary vascular remodeling in distal 
pulmonary arteries in female normoxic and hypoxic mice with representative images (right) of pulmonary 
arteries (Elastin Van Giesen stain; scale bars = 50 microns). Results are mean ±SEM, n=8 per group. 
**p<0.01 vs Normoxic vehicle, †p<0.05 versus hypoxic vehicle-treated mice, determined by 2-way ANOVA 
with Tukey’s post-hoc test.  
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Supplemental Figure IX: Oxidative stress marker,8-hydroxyguanosine, is increased in the lungs of 
female SERT+ mice. Lung sections obtained from wild-type (WT) and SERT+ mice treated with the 5-
HT1BR antagonist (SB216641) or vehicle, were immunostained for the oxidative-stress marker 8-
hydroxyguanosine (8-OHG). Sections were counterstained with the nuclear stain DAPI (4′,6-diamidino-2-
phenylindole). Scale bar: 50 μm (A). 8-OHG mean fluorescence intensity was measured in lung sections 
using ImageJ software; n = 4 (B). *p<0.05; ***p<0.01 vs WT vehicle; †p<0.05 vs SERT+ vehicle, 
determined by 2-way ANOVA with Tukey’s post-hoc test.  WT = wild-type, SERT+ = serotonin transporter 
overexpression. SB216641 = 5-HT1BR antagonist.
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Supplemental Figure X: Schematic of putative role of serotonin in hPASMCs. Actions of serotonin in 
PASMCs are mediated not only via the 5-HT1BR and SERT, but also involve the activation of Noxs, 
particularly Nox1, which leads to .O2- and H2O2 production. Excessive ROS production coupled with 
impaired Nrf2-mediated antioxidant mechanisms in response to serotonin may promote oxidation of PTPs 
and total protein carbonylation and proteins involved in mitogenic and fibrotic effects, leading to deleterious 
oxidative stress and pulmonary vascular remodeling. +  activation; - inhibition.
